Canagliflozin (hemihydrate): SGLT2 Inhibitor for Glucose Metabolism Research

Executive Summary: Canagliflozin (hemihydrate), available as APExBIO SKU C6434, is a highly pure SGLT2 inhibitor designed for scientific research applications (APExBIO). This compound selectively inhibits renal sodium-glucose co-transporter 2, supporting studies in glucose homeostasis and diabetes mellitus research (Fexinidazolesupply). Recent peer-reviewed evidence confirms that Canagliflozin does not inhibit the mTOR pathway, clarifying its pathway specificity (Breen et al., 2025). The product is quality-controlled (≥98% purity, HPLC/NMR) and recommended for short-term use in solution to preserve efficacy. Its robust solubility in DMSO (≥83.4 mg/mL) and ethanol (≥40.2 mg/mL), and strict non-medical use, make it suitable for reproducible metabolic disorder research workflows.

Biological Rationale

Canagliflozin (hemihydrate) is a synthetic small molecule that targets SGLT2, a key transporter responsible for renal glucose reabsorption. SGLT2 activity in the proximal tubule of the kidney regulates systemic glucose homeostasis by reclaiming filtered glucose from urine. Inhibition of SGLT2 reduces renal glucose reabsorption, leading to increased urinary glucose excretion and decreased blood glucose levels. This mechanism is foundational in studies seeking to model or modulate glucose metabolism, especially in the context of diabetes mellitus and related metabolic disorders. Canagliflozin is structurally defined as (2S,3R,4R,5S,6R)-2-(3-((5-(4-fluorophenyl)thiophen-2-yl)methyl)-4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol, with a molecular formula of C24H26FO5.5S and molecular weight of 453.52 (APExBIO).

Mechanism of Action of Canagliflozin (hemihydrate)

Canagliflozin (hemihydrate) selectively inhibits sodium-glucose co-transporter 2 (SGLT2) in renal proximal tubule cells. By blocking SGLT2-mediated glucose reabsorption, the compound increases urinary glucose elimination, thereby lowering systemic glucose levels. This mechanism is independent of insulin pathways and does not impact the mechanistic target of rapamycin (mTOR) signaling, as confirmed in recent drug-sensitized yeast models (Breen et al., 2025). The specificity for SGLT2 over other metabolic or kinase pathways enables focused studies on glucose homeostasis and renal function without confounding off-target effects. The product's solubility profile (≥83.4 mg/mL in DMSO; ≥40.2 mg/mL in ethanol) supports diverse experimental applications, including in vitro, ex vivo, and cell-based assays (Fexinidazolesupply).

Evidence & Benchmarks

• Canagliflozin (hemihydrate) achieves ≥98% chemical purity as validated by HPLC and NMR analyses (APExBIO).
• Solubility is robust in DMSO (≥83.4 mg/mL) and ethanol (≥40.2 mg/mL), but the compound is insoluble in water (APExBIO).
• Canagliflozin demonstrates no detectable inhibition of mTOR or TORC1 in yeast-based drug sensitivity assays, confirming pathway selectivity (Breen et al., 2025).
• Recommended storage is at -20°C with blue ice shipping for small molecules; solutions should not be stored long-term (APExBIO).
• Not intended for diagnostic or therapeutic use; strictly for research applications as specified by the supplier (APExBIO).

Applications, Limits & Misconceptions

Canagliflozin (hemihydrate) is utilized in research on diabetes mellitus, glucose homeostasis, and renal glucose reabsorption inhibition. Its high specificity for SGLT2 facilitates pathway-resolved metabolic disorder research. For instance, this analysis previously covered SGLT2 selectivity; here, we further clarify non-mTOR activity with new yeast model evidence. In contrast, Canagliflozin Hemihydrate: Precision SGLT2 Inhibitor… focused on pathway reproducibility, which our article extends by benchmarking purity and solubility for advanced metabolic workflows. Finally, this workflow guide offered practical assay integration tips; the present article updates protocol recommendations in light of recent selectivity data.

Common Pitfalls or Misconceptions

• Not an mTOR inhibitor: Canagliflozin (hemihydrate) does not inhibit mTOR or TORC1 at concentrations active in SGLT2 assays (Breen et al., 2025).
• Not water-soluble: The compound is insoluble in water; use DMSO or ethanol for dissolution (APExBIO).
• Not for therapeutic use: Supplied strictly for research purposes; not approved for clinical or diagnostic applications (APExBIO).
• Solutions are unstable long-term: Do not store prepared solutions for extended periods; use promptly after preparation (APExBIO).
• No effect on cell viability unrelated to SGLT2: Activity is restricted to SGLT2-mediated pathways; off-target cytotoxicity is unsupported by current data (Breen et al., 2025).

Workflow Integration & Parameters

For optimal use, Canagliflozin (hemihydrate) should be dissolved in DMSO or ethanol at recommended concentrations, then diluted as required for cell culture or in vitro assays. Store powder at -20°C and minimize freeze-thaw cycles to preserve integrity. Quality control includes batch-level HPLC and NMR documentation. Use only freshly prepared solutions and discard unused aliquots. Integration into glucose metabolism studies should align with validated SGLT2 pathway assays and avoid conditions requiring mTOR pathway interrogation, as no cross-inhibition occurs. For further protocol optimization, see the product page and scenario-driven guides linked above.

Conclusion & Outlook

Canagliflozin (hemihydrate) from APExBIO is a validated, high-purity SGLT2 inhibitor for research in glucose metabolism, diabetes, and renal glucose handling. Its pathway specificity and absence of mTOR inhibition distinguish it from many metabolic modulators. Reliable solubility and strict quality standards support reproducible experimental design. Ongoing research may reveal additional metabolic applications, but current evidence supports its use as a benchmark tool for SGLT2-focused studies.